Rechallenge ou Regorafenib : l’ordre importe peu !Marco Maria GERMANI, Pise (Italie) - LBA32 - Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO
TALENTop : quand la chirurgie fait mieux que la maintenance immunoHui-Chuan SUN, Shanghai (Chine) - 1469MO - Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial
DYNAMIC-III : quand la désescalade manque un peu de souffleJeanne TIE, Melbourne (Australie, VIC) - BA9 - ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG),
Encore un triplet sans envol : l’ajout de tiragolumab n’élève pas le niveau du duo Atézo/BévaRichard S. FINN, Los Angeles (USA) - LBA50 - IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)
Triplet-HCC : ipilimumab, l’invité de trop ?Philippe MERLE, Lyon (France) - 1471MO - Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC
De la phase Ib à la désillusion : RegoNivo perd le match face à la chimioDavid GOLDSTEIN, Sydney (Australie) - LBA80 - Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
TNE pancréatique sporadique non-sécrétante de <2cm : on n’y touche pas !Stefano PARTELLI, Milan (Italie) - LBA36 - Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms ≤2 cm: A prospective international observational multicentric cohort study (ASPEN study)
Rechallenge par anti-EGFR : stop ou encore ?Clara MONTAGUT, Barcelone (Espagne) - LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial
PHERFLOT : quand FLOT, HER2 et immuno font bon ménageJoseph TINTELNOT, Hambourg (Allemagne) - 2095MO - Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321),
Traitement péri-opératoire des adénocarcinomes œsogastriques : la place du Durvalumab se confirme !Josep TABERNERO, Barcelone (Espagne) - LBA81 - Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma